Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group - PubMed
Clinical Trial
. 1998 Dec;16(12):3744-51.
doi: 10.1200/JCO.1998.16.12.3744.
N E Breslow, J B Beckwith, J Z Finklestein, P Grundy, P R Thomas, T Kim, S Shochat, G Haase, M Ritchey, P Kelalis, G J D'Angio
Affiliations
- PMID: 9850017
- DOI: 10.1200/JCO.1998.16.12.3744
Clinical Trial
Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group
D M Green et al. J Clin Oncol. 1998 Dec.
Abstract
Purpose: National Wilms' Tumor Study (NWTS)-4 was designed to evaluate the efficacy, toxicity, and cost of the administration of different regimens for the treatment of Wilms' tumor (WT).
Patients and methods: Between August 6, 1986 and September 1, 1994, 905 previously untreated children aged younger than 16 years with stage II favorable histology (FH) WT (low-risk [LR]), stages III to IV FH WT, or stages I to IV clear-cell sarcoma of the kidney (high-risk[HR]) were randomized after the completion of 6 months of chemotherapy to discontinue (short) or continue for 9 additional months (long) treatment with chemotherapy regimens that included vincristine and either divided-dose (standard [STD]) courses (5 days) or single-dose (pulse-intensive [PI]) treatment with dactinomycin. HR patients also received either divided-dose (STD) courses (3 days) or single-dose (PI) treatment with doxorubicin.
Results: The 4-year relapse-free survival (RFS) rates after the second randomization for LR patients were 83.7% for the 190 patients treated with short and 88.2% for the 187 patients treated with long chemotherapy (P = .11). The 4-year RFS rates after the second randomization for HR FH patients were 89.7% for the 256 patients treated with short and 88.8% for the 246 patients treated with long chemotherapy (P = .87). The charge for treatment with the short PI treatment regimens for all children with stages I through IV FH WT was approximately one half of that with the long STD treatment regimens.
Conclusion: The short administration schedule for the treatment of children with WT is no less effective than the long administration schedule and can be administered at a substantially lower total treatment cost.
Similar articles
-
Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy PE, Thomas PR, Kim T, Shochat SJ, Haase GM, Ritchey ML, Kelalis PP, D'Angio GJ. Green DM, et al. J Clin Oncol. 1998 Jan;16(1):237-45. doi: 10.1200/JCO.1998.16.1.237. J Clin Oncol. 1998. PMID: 9440748 Clinical Trial.
-
Seibel NL, Li S, Breslow NE, Beckwith JB, Green DM, Haase GM, Ritchey ML, Thomas PR, Grundy PE, Finklestein JZ, Kim T, Shochat SJ, Kelalis PP, D'Angio GJ. Seibel NL, et al. J Clin Oncol. 2004 Feb 1;22(3):468-73. doi: 10.1200/JCO.2004.06.058. J Clin Oncol. 2004. PMID: 14752069 Clinical Trial.
-
Green DM, Breslow NE, Evans I, Moksness J, Finklestein JZ, Evans AE, D'Angio GJ. Green DM, et al. J Natl Cancer Inst Monogr. 1995;(19):21-5. J Natl Cancer Inst Monogr. 1995. PMID: 7577200 Clinical Trial.
-
Treatment of Wilms' tumour. Current recommendations.
Mehta MP, Bastin KT, Wiersma SR. Mehta MP, et al. Drugs. 1991 Nov;42(5):766-80. doi: 10.2165/00003495-199142050-00004. Drugs. 1991. PMID: 1723373 Review.
-
Adult Wilms' tumor. Report of two cases and review of the literature.
Hentrich MU, Meister P, Brack NG, Lutz LL, Hartenstein RC. Hentrich MU, et al. Cancer. 1995 Jan 15;75(2):545-51. doi: 10.1002/1097-0142(19950115)75:2<545::aid-cncr2820750218>3.0.co;2-c. Cancer. 1995. PMID: 7812923 Review.
Cited by
-
Green DM, Kun LE, Matthay KK, Meadows AT, Meyer WH, Meyers PA, Spunt SL, Robison LL, Hudson MM. Green DM, et al. Pediatr Blood Cancer. 2013 Jul;60(7):1083-94. doi: 10.1002/pbc.24487. Epub 2013 Feb 15. Pediatr Blood Cancer. 2013. PMID: 23418018 Free PMC article. Review.
-
Iaboni DSM, Chi YY, Kim Y, Dome JS, Fernandez CV. Iaboni DSM, et al. Pediatr Blood Cancer. 2019 Jan;66(1):e27430. doi: 10.1002/pbc.27430. Epub 2018 Aug 30. Pediatr Blood Cancer. 2019. PMID: 30160355 Free PMC article.
-
Green DM, Breslow NE, D'Angio GJ, Malogolowkin MH, Ritchey ML, Evans AE, Beckwith JB, Perlman EJ, Shamberger RC, Peterson S, Grundy PE, Dome JS, Thomas PR, Kalapurakal JA. Green DM, et al. Pediatr Blood Cancer. 2014 Jan;61(1):134-9. doi: 10.1002/pbc.24658. Epub 2013 Aug 23. Pediatr Blood Cancer. 2014. PMID: 24038736 Free PMC article. Clinical Trial.
-
O'Leary M, Krailo M, Anderson JR, Reaman GH; Children's Oncology Group. O'Leary M, et al. Semin Oncol. 2008 Oct;35(5):484-93. doi: 10.1053/j.seminoncol.2008.07.008. Semin Oncol. 2008. PMID: 18929147 Free PMC article. Review.
-
Childhood renal tumor: a report from a Chinese Children's Cancer Group.
Cai J, Pan C, Lu Q, Yan J, Ju X, Ma F, Zhu Y, Liu Q, Sun L, Jiang L, Cao L, Li F, Liu Z, Qiao L, Huang D, Tian X, Tang J. Cai J, et al. Biomed Res Int. 2014;2014:894341. doi: 10.1155/2014/894341. Epub 2014 Jul 24. Biomed Res Int. 2014. PMID: 25147822 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous